From Medscape Neurology

Coverage from the

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2022

February 24 - 26, 2022; West Palm Beach, Florida and Virtual

February 24 - 26, 2022 West Palm Beach, Florida and Virtual

ACTRIMS 2022 DMTs Tied to Lower MS Relapse During Reproductive Therapy Among patients with multiple sclerosis receiving assisted reproductive therapy, risk for relapse is increased only in those not treated with disease modifying therapy, new research suggests.
Medscape Medical News, March 4, 2022
ACTRIMS 2022 Stem Cell Transplantation a Potential Game Changer for MS? Relapse rates dropped to zero after an intensive regimen of autologous hematopoietic stem cell transplant, but improvement is greater with lower baseline disability.
Medscape Medical News, March 3, 2022

Conference News

ACTRIMS 2022 Does MS Drug Dosing Regimen Need Revising?
Medscape Medical News, March 15, 2022
ACTRIMS 2022 Early MS Biomarkers May Improve Prediction of Long-term Outcomes
Medscape Medical News, March 10, 2022
ACTRIMS 2022 DMTs Tied to Lower MS Relapse During Reproductive Therapy
Medscape Medical News, March 4, 2022
ACTRIMS 2022 B-Cell Therapy for MS May Affect COVID Vaccine Response
Medscape Medical News, March 4, 2022

ACTRIMS 2022 Stem Cell Transplantation a Potential Game Changer for MS?
Medscape Medical News, March 3, 2022
ACTRIMS 2022 Investigational MS Drug Safe, Effective at 18 Months
Medscape Medical News, March 2, 2022
ACTRIMS 2022 Spinal Cord Atrophy Predicts 'Silent Progression' in MS
Medscape Medical News, February 28, 2022
ACTRIMS 2022 Evidence Mounts for Paramagnetic Rim Lesions in Diagnosing MS
Medscape Medical News, February 28, 2022

Popular News from ACTRIMS 2021

Vitamin D Deficiency Linked to Early Cognitive Impairment in MS People with MS and low levels of serum vitamin D show significant reductions in information processing speed versus those with normal levels of the vitamin concentrations.
Medscape Medical News, Mar 01, 2021
Anti-CD20s Linked to Higher COVID-19 Severity in MS Because other DMTs were not linked to extra risk, experts are recommending their continued use in treating MS.
Medscape Medical News, Mar 05, 2021
Erythropoietin Falls Short of Neuroprotection in Optic Neuritis A higher rate of conversion to multiple sclerosis in the placebo group offered a glimmer of hope for treatment in TONE, a phase 3 randomized trial, but caveats loom large.
Medscape Medical News, Mar 04, 2021

Medscape Neurology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resource

Multiple Sclerosis News & Perspectives